Save on registration when you also register to attend the 5 April event, “Early Preparation is Key to Successful FDA Panel Reviews."
6 April 2016
5:30–8:30 pm
AbbVie
Abbott Park, IL
Today’s exciting medical innovations should be shining moments for biopharma. Instead, companies are increasingly being tarnished by a backlash over prices. Increased scrutiny means the old way of justifying a therapy’s price is obsolete. Influential stakeholders are demanding collaboration and transparency to maximize patient access.
We’ve seen payment reforms such as bundled payments, global health budgets, greater provider risk for outcomes, payer consolidation and new insurance designs that shift more costs to patients. And this is just the tip of the iceberg.
Traditionally, biopharma companies have addressed these risks by speaking to the value of innovations. Increasingly, however, that value analysis is not resonating with payers, providers, and even patients. They are shifting the discussion, changing the dialogue, and altering the debate. Rather than speaking of “the value of innovation,” these stakeholders are criticizing the price of treatments and concerned about affordability.
Unquestionably, affordability is a huge issue that must be addressed – but it is really step two. Step one is the need to get the value question right. It is clear that simply developing products to meet scientifically-defined “unmet medical need” is not sufficient in today’s markets.
Learning Objectives:
- Identify key issues affecting the market access landscape
- Apply potential models for creating and communicating a product’s value
- Integrate new ideas for communicating a product’s rationale for patients, providers and payers
A light meal will be provided for all attendees and participants are eligible to claim two (2) continuing education and/or RAC recertification points.
Date/Time:
Wednesday, 6 April 6016
5:30–6:00 pm Registration, Check-In
6:00–7:00 pm Networking and Dinner
7:00–8:30 pm Speaker Presentation and Q/A Session
Location:
AbbVie
100 Abbott Park Road
Building AP30LL
Conference Center Room E
Abbott Park, IL
Find directions online or call +1 224 667 6100
Registration:
RAPS is offering a discounted registration fee when registering for both events. Contact RAPS customer service at +1 301 770 2920 ext. 200 to get the special rate.
Registration Fee (for one event):
RAPS Members: $40 Nonmembers: $55
Registration Fee (when registering for both events):
RAPS Members: $30 Nonmembers: $45
Speaker:
Jane Horvath, MHSA, market access lead, 3D Communiations
Jane Horvath, MHSA, leads 3D's Market Access and Value Communications team. Jane brings nearly 25 years of experience in health policy and reimbursement issues to 3D clients. As Executive Director of Health Policy and Reimbursement at Merck for a decade, she identified the business implications of state and federal policy developments including the Medicare prescription drug program, Medicaid, health information technology, Big Data access and methods, 340B, and reformed commercial markets. Prior to Merck, Jane was Deputy Director of the Robert Wood Johnson Foundation project at Johns Hopkins University School of Public Health, conducting research and devising policy on care management and financing for people with chronic conditions. Jane also held a series of high profile government positions. This included work as Deputy Assistant Secretary for Legislation in the US Department of Health and Human Services, responsible for legislative policy for all health-related areas, including Medicare, Medicaid, and prescription drug pricing. Recently Jane was Vice President at Breakaway Policy Strategies focused on biopharma issues and clients. Jane earned a Masters of Health Services Administration from the George Washington University.
Local Contact:
Carol Cooper, RAC, RAPS Chicago Chapter Co-Chair
Joe Orlowski, RAC, RAPS Chicago Chapter Co-Chair
RAPS Contact:
Wesley Carr, +1 301 770 2920